1. Protocol to generate two distinct standard-of-care murine glioblastoma models for evaluating novel combination therapies.
- Author
-
Pineau R, Le Reste PJ, Avril T, Jarry U, Chevet E, and Pelizzari-Raymundo D
- Subjects
- Animals, Mice, Cell Line, Tumor, Humans, Xenograft Model Antitumor Assays methods, Glioblastoma pathology, Brain Neoplasms pathology, Disease Models, Animal, Standard of Care
- Abstract
In cancer research, murine models play a crucial role as highly valuable preclinical tools. Here, we present a protocol to generate a murine model of glioblastoma through the direct intracranial injection of tumor cells. We describe steps for cell culture, intracranial implantation, and standard-of-care treatments. We then detail procedures for monitoring tumor growth using bioluminescent imaging. For complete details on the use and execution of this protocol, please refer to Pelizzari-Raymundo et al.
1 ., Competing Interests: Declaration of interests E.C. is the founder of Thabor Therapeutics; D.P.-R. and E.C. are authors of the patent PCT/EP2023/050228—Compounds containing a hydroxyphenyl moiety and their use, 2022., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF